Breast Cancer Research
The Royal Marsden NHS Foundation Trust is involved in clinical research focused on ER positive HER2 negative breast cancer, with particular attention to disease monitoring and treatment decisions guided by molecular evidence.
- ER positive HER2 negative breast cancer
- Early relapse detection
- Circulating tumour DNA tracking
Its research activity in this area centres on identifying molecular signs of recurrence and evaluating endocrine-based treatment strategies for patients with detectable ctDNA during adjuvant therapy.
Minimal Residual Disease and Molecular Surveillance
The sponsor supports research into molecular relapse detection in breast cancer, using circulating tumour DNA as a marker of residual disease and recurrence risk.
- ctDNA detection
- Molecular relapse
- Residual disease monitoring
This area reflects a strong interest in refining surveillance approaches for patients receiving adjuvant endocrine therapy.
Endocrine Therapy in Breast Cancer
Clinical research activity includes evaluation of endocrine therapy strategies for patients with hormone receptor-positive breast cancer, particularly those with evidence of molecular recurrence.
- Adjuvant endocrine therapy
- Relapse-free survival
- Hormone receptor-positive disease
The focus extends to treatment pathways relevant to patients whose disease remains sensitive to hormonal manipulation.
Targeted Treatment for Molecularly Detected Relapse
The sponsor’s trial portfolio includes interest in palbociclib and fulvestrant for breast cancer patients with detectable ctDNA, linking molecular surveillance with targeted intervention.
- Palbociclib
- Fulvestrant
- Molecularly guided treatment
This research domain is directed toward improving management options for ER positive HER2 negative breast cancer when early molecular evidence of relapse is present.
